Home » FDA Grants SGX Orphan-Drug Designation for Troxatyl
FDA Grants SGX Orphan-Drug Designation for Troxatyl
Structural GenomiX's lead product candidate, Troxatyl, has received orphan-drug status from the FDA.
Troxatyl (troxacitabine) is a novel nucleoside analog being evaluated by the company in a Phase I/II trial for the treatment of relapsed acute myelogenous leukemia (AML) and in a Phase I/II trial for the treatment of various solid tumors. Structural GenomiX plans to complete the Phase I/II AML trial and progress Troxatyl into a Phase II trial in relapsed and/or refractory adult AML patients in mid-2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May